ArticlePloS one2007
Identification of novel high-frequency DNA methylation changes in breast cancer.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 112 citations in OpenAlex.
- Combination of Hotspot Mutations With Methylation and Fragmentomic Profiles to Enhance Multi-Cancer Early Detection.Cancer medicine · 2025Article
- Article
- A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nature cancer · 2022Article
- Article
- The influence of obesity on folate status, DNA methylation and cancer-related gene expression in normal breast tissues from premenopausal women.Epigenetics · 2021Article
- Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2019Review
- Enhanced synaptic plasticity and spatial memory in female but not male FLRT2-haplodeficient mice.Scientific reports · 2018Article
- Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.Diseases (Basel, Switzerland) · 2017Review
- Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells.Scientific reports · 2017Article
- Epigenome-wide association study of smoking and DNA methylation in non-small cell lung neoplasms.Oncotarget · 2016Article
- Epigenetic DNA Methylation Profiling with MSRE: A Quantitative NGS Approach Using a Parkinson's Disease Test Case.Frontiers in genetics · 2016Article
- Role of epigenetic modifications in luminal breast cancer.Epigenomics · 2015Review
- An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature.Omics : a journal of integrative biology · 2014Article
- A novel method for identification and quantification of consistently differentially methylated regions.PloS one · 2014Article
- An emerging place for lung cancer genomics in 2013.Journal of thoracic disease · 2013Review
- Integrated genomic analysis of breast cancers.Balkan journal of medical genetics : BJMG · 2012Article
- Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers.Cancer medicine · 2012Review
- DNA methylation as clinically useful biomarkers-light at the end of the tunnel.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Article
- Epigenetic alterations in bladder cancer and their potential clinical implications.Advances in urology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent data have revealed that epigenetic alterations, including DNA methylation and chromatin structure changes, are among the earliest molecular abnormalities to occur during tumorigenesis. The inherent thermodynamic stability of cytosine methylation and the apparent high specificity of the alterations for disease may accelerate the development of powerful molecular diagnostics for cancer. We report a genome-wide analysis of DNA methylation alterations in breast cancer. The approach efficiently identified a large collection of novel differentially DNA methylated loci (approximately 200), a subset of which was independently validated across a panel of over 230 clinical samples. The differential cytosine methylation events were independent of patient age, tumor stage, estrogen receptor status or family history of breast cancer. The power of the global approach for discovery is underscored by the identification of a single differentially methylated locus, associated with the GHSR gene, capable of distinguishing infiltrating ductal breast carcinoma from normal and benign breast tissues with a sensitivity and specificity of 90% and 96%, respectively. Notably, the frequency of these molecular abnormalities in breast tumors substantially exceeds the frequency of any other single genetic or epigenetic change reported to date. The discovery of over 50 novel DNA methylation-based biomarkers of breast cancer may provide new routes for development of DNA methylation-based diagnostics and prognostics, as well as reveal epigenetically regulated mechanism involved in breast tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.